Skip to main content
Premium Trial:

Request an Annual Quote

Generics on Their Mind

Sanofi-Aventis will be expanding into generics, says the Wall Street Journal, while cutting its research and development. The generic group will be reshuffled to focus on emerging markets where drug sales are on the rise. The Health Blog adds that Sanofi recently bought two Latin American generic-drug companies as well as a Czech one. The Health Blog also notes that Johnson & Johnson is contemplating selling generics outside the US, Pfizer has a deal with Aurobindo Pharma and Claris Lifesciences to market generics in emerging markets, and that AstraZeneca, Merck, and Novartis are also dipping their toes into generics.

On a related note, Japan has approved its first generic biotech drug, Somatropin. This Novartis drug treats growth hormone deficiency in children or associated with Turner's syndrome or chronic renal insufficiency.

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.